<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INDAPAMIDE</span><br/>(in-dap'a-mide)<br/><span class="topboxtradename">Lozide <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Lozol<br/></span><b>Classifications:</b> <span class="classification">electrolytic and water balance agent</span>; <span class="classification">thiazide-like diuretic</span><br/><b>Prototype: </b>Hydrochlorothiazide<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.25, 2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Sulfonamide derivative which has both diuretic and direct vascular effects. Action mechanism is similar to that of the thiazide
         diuretics. Principal site of action is on the proximal portion of the distal renal tubules. Enhances excretion of sodium,
         potassium, and water by interfering with sodium transfer across renal epithelium of the tubules.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Hypotensive activity in the hypertensive patient appears to result from a decrease in plasma and extracellular fluid volume,
         decreased peripheral vascular resistance, direct arteriolar dilation, and calcium channel blockade. Augments the action of
         other hypotensive agents.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Alone or with other antihypertensives as step 1 agent in the management of hypertension in patients who have failed to respond
         to diet, exercise, or weight reduction.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Edema associated with CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to indapamide or other sulfonamide derivatives, anuria.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Electrolyte imbalance, hypokalemia, severe renal disease; impaired hepatic function or progressive liver disease; prediabetic
         and type II diabetic patient, hyperparathyroidism, thyroid disorders; SLE; sympathectomized patient; history of gout. Safe
         use during pregnancy (category B), lactation, or children is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, Edema</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg once/d, may increase to 5 mg/d if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to reduce GI irritation.</li>
<li>Administer in a.m. to prevent nocturia. Urge patient to take at least 240 mL (8 oz) of fluid (if allowed) with the medication.</li>
<li>Store in tight, light-resistant container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, fatigue, weakness, muscle cramps or spasm, paresthesia, tension, anxiety, nervousness, agitation, vertigo,
      insomnia, mental depression, blurred vision, drowsiness. <span class="typehead">CV:</span> Orthostatic hypotension, PVCs, dysrhythmias, flushing, palpitation. <span class="typehead">GI:</span> Dry mouth, anorexia, nausea, vomiting, diarrhea, constipation, abdominal cramps or pain. <span class="typehead">Urogenital:</span> Urinary frequency, nocturia, polyuria, glycosuria, impotence or reduced libido. <span class="typehead">Skin:</span> Rash, hives, pruritus, vasculitis, photosensitivity. <span class="typehead">Metabolic:</span> Dilutional hyponatremia, <span class="speceff-common">hyperuricemia,</span> exacerbation of gout; <span class="speceff-common">hypokalemia,</span> hyperglycemia, hypochloremia, hypercalcemia, increased BUN or creatinine, weight loss, exacerbation of SLE; increased cholesterol. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Since indapamide may cause hypercalcemia (and hypophosphatemia), it is generally withheld before tests for <span class="alt">parathyroid function</span> are performed.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Effects of <b>diazoxide</b> and indapamide intensified; increased risk of <b>digoxin</b> toxicity with hypokalemia; decreased renal <b>lithium</b> clearance may increase risk of <b>lithium</b> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 22.5 h. <span class="typehead">Duration:</span> Up to 36 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 60% excreted in urine; 1623% excreted in feces. <span class="typehead">Half-Life:</span> 1418 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP periodically throughout therapy.</li>
<li>Lab tests: Obtain baseline and periodic BUN, serum creatinine, uric acid, blood glucose, serum electrolytes, and fluid balance.</li>
<li>Monitor for digitalis toxicity with concurrent therapy.</li>
<li>
            							Note: Electrolyte imbalances may be clinically serious with protracted vomiting and diarrhea, excessive sweating, GI drainage, and
            paracentesis.
            						
         </li>
<li>Report promptly signs of hyponatremia or hypokalemia (see Appendix F).</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of decreased urine output, dizziness, weakness or muscle cramps, nausea, jaundice, or blurred vision.</li>
<li>Take precautions from sun exposure because of risk of photosensitivity.</li>
<li>Record weight at least every other day; inspect ankles and legs for edema. Report unexplained, progressive weight gain [e.g.,
            11.5 kg (23 lb) in 23 d].
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>